MedTrace Logo

Phase II Study for the Diagnosis and Functional Assessment of CAD Using Transthoracic-Echodoppler

NCT01593644 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2012-09-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and tolerance of a dipyridamole/adenosine combination given intravenously, as a slow bolus and at low doses to adenosine alone (given at its recommended dosage adjusted to patients' weight) for coronary flow reserve assessment (in 60-75 patients with stable ischemic heart disease) using transthoracic echodoppler

Conditions

  • Ischemic Heart Disease

Interventions

DRUG

adenosine + dipyridamole

adenosine / dipyridamole combination given intravenously as a slow bolus at low doses

Sponsors & Collaborators

  • Adenobio N.V

    lead OTHER

Principal Investigators

  • Patrick Meimoun, PhD · Centre Hospitalier de Compiègne

Study Design

Allocation
NA
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01593644 on ClinicalTrials.gov